Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: jackal 44 who wrote (30481)	12/18/1998 7:49:00 AM
From: AV8R	Respond to of 119973

ASTM - More news, this one will rocket soon! Thursday December 17, 7:46 pm Eastern Time Aastrom gets European OK for cell system ANN ARBOR, Mich., Dec 17 (Reuters) - Aastrom Biosciences Inc. said Thursday it received European approval to market its AastromReplicell cell production system liquid products, part of its SC-I therapy kit, to produce bone marrow cells for use in stem cell therapy. The announcement follow and earlier approval of the system's instrumentation platform, and now allows the company to begin marketing the kit in Europe, the company said. Aastrom recently announced the start of the first U.S. pivotal clinical trial of the SC-I therapy kit as an alternative method of cell collection for use in stem cell therapy. AastromReplicell is designed to produce cells useful in a broad range of therapies. Stem cell transplants are commonly used to treat patients with cancer or other diseases who have undergone extensive chemotherapy or radiation treatments. These treatments can damage or destroy the patient's bone marrow and blood and immune system cells. As a result, they sometimes need a stem cell transplant to restore their vital cells and tissues. Shares of Aastrom were up 13/64 at 3-29/64.